← Back to search
LEIDOS BIOMEDICAL RESEARCH INC
FREDERICK, MD, 21702
UnclaimedClaim this profile (free)
Prime contracting experience
Showing the 50 most recent of 238 records from government sources. Past participation is not evidence of current teaming interest.
| Role | Agency | Description | Vehicle | Obligated | Action date | Period |
|---|---|---|---|---|---|---|
| Prime | Department of Health and Human Services National Institutes of Health | NCI OPERATIONAL TASK ORDER, FY26-FY27 | 75N91019D00024USAspending | $825,985,691 | Sep 30, 2026 | Aug 31, 2025 – Aug 30, 2027 |
| Prime | Department of Health and Human Services National Institutes of Health | FUNCTIONAL PRECISION MEDICINE AND RESPONSE ASSAYS | 75N91019D00024USAspending | $72,167,416 | Sep 29, 2026 | Sep 29, 2026 – Sep 28, 2031 |
| Prime | Department of Health and Human Services National Institutes of Health | PALM004: AN OBSERVATIONAL STUDY OF THE NATURAL HISTORY OF BUNDIBUGYO VIRUS DISEASE | 75N91019D00024USAspending | $11,725,031 | Sep 25, 2026 | Sep 25, 2026 – Sep 24, 2029 |
| Prime | Department of Health and Human Services National Institutes of Health | THE NIAID DIR FY26-27 OPERATIONAL TASK ORDER | 75N91019D00024USAspending | $17,766,274 | Sep 25, 2026 | Aug 31, 2025 – Aug 30, 2027 |
| Prime | Department of Health and Human Services National Institutes of Health | MANUFACTURING PROCESS DEVELOPMENT OF 4-HB | 75N91019D00024USAspending | $1,270,276 | Sep 25, 2026 | Sep 15, 2025 – Sep 14, 2030 |
| Prime | Department of Health and Human Services National Institutes of Health | NIAID DCR FY26-27 OPERATIONAL TASK ORDER | 75N91019D00024USAspending | $137,656,019 | Sep 25, 2026 | Aug 31, 2025 – Aug 30, 2026 |
| Prime | Department of Health and Human Services National Institutes of Health | NIAID / CHILDRENS NATIONAL MEDICAL CENTER JOINT CLINICAL RESEARCH PROGRAM (JCRP) IMMUNOLOGIC AND INFECTIOUS DISEASES CLINICAL RESEARCH | 75N91019D00024USAspending | $10,001,104 | Sep 25, 2026 | Sep 2, 2022 – Sep 1, 2027 |
| Prime | Department of Health and Human Services National Institutes of Health | CLINICAL MATERIAL TECHNOLOGY DEVELOPMENT AND PILOT MANUFACTURING | 75N91019D00024USAspending | $17,712,309 | Sep 24, 2026 | Sep 24, 2026 – Sep 23, 2031 |
| Prime | Department of Health and Human Services National Institutes of Health | NCATS-DPI-22-0101 - CREATION OF AN OPEN-SOURCE PROCESS TO MANUFACTURE AAV VECTOR-BASED GENE THERAPY CANDIDATES FOR NON-COMMERCIAL CLINICAL STUDIES | 75N91019D00024USAspending | $13,973,744 | Sep 23, 2026 | Sep 12, 2022 – Sep 11, 2027 |
| Prime | Department of Health and Human Services National Institutes of Health | INTEGRATED DMPK AND TOXICOLOGY PROFILING OF NCATS/TDB MEDICINAL CHEMISTRY LEAD CANDIDATES | 75N91019D00024USAspending | $1,683,296 | Sep 23, 2026 | Sep 28, 2026 – Sep 27, 2031 |
| Prime | Department of Health and Human Services National Institutes of Health | CMC SUPPORT FOR NCATS RARE DISEASE PLATFORM GENE THERAPY TRIAL PROJECTS | 75N91019D00024USAspending | $30,072,496 | Sep 23, 2026 | Sep 23, 2019 – Mar 31, 2031 |
| Prime | Department of Health and Human Services National Institutes of Health | FFRDC MOONSHOT PORTFOLIO TASK ORDER | 75N91019D00024USAspending | $33,139,792 | Sep 22, 2026 | Aug 31, 2019 – Sep 30, 2027 |
| Prime | Department of Health and Human Services National Institutes of Health | ENABLING NCI CLINICAL & RESEARCH DATA SHARING | 75N91019D00024USAspending | $98,565,259 | Sep 22, 2026 | Aug 31, 2021 – Feb 28, 2028 |
| Prime | Department of Health and Human Services National Institutes of Health | HHSN261201500003I; HHSN26100071; 400.021.0071.0001; NCI CBIIT; APPROPRIATED; EXPAND DATA COMMONS; 09/14/18-09/13/23 | HHSN261201500003IUSAspending | $72,263,032 | Sep 17, 2026 | Sep 11, 2018 – Aug 31, 2029 |
| Prime | Department of Health and Human Services National Institutes of Health | NCI-ARCDCTD-26-0055 - CPTAC BIOSPECIMEN ACQUISITION, PROCESSING, AND DISTRIBUTION | 75N91019D00024USAspending | $4,538,288 | Sep 15, 2026 | Sep 21, 2026 – Sep 20, 2027 |
| Prime | Department of Health and Human Services National Institutes of Health | DRUG PRODUCT FORMULATION DEVELOPMENT, GMP MANUFACTURE, AND LONG-TERM STABILITY STUDIES OF BITOX FOR PHASE I CLINICAL TRIALS | 75N91019D00024USAspending | $1,649,757 | Sep 14, 2026 | Sep 15, 2023 – Sep 14, 2026 |
| Prime | Department of Health and Human Services National Institutes of Health | INTEGRATED DMPK AND TOXICOLOGY PROFILING OF NCATS/TDB MEDICINAL CHEMISTRY LEAD CANDIDATES | 75N91019D00024USAspending | $1,088,780 | Sep 14, 2026 | Sep 21, 2026 – Sep 20, 2029 |
| Prime | Department of Health and Human Services National Institutes of Health | CORE SUPPORT FOR THE IMMUNE CELL NETWORK | 75N91019D00024USAspending | $26,946,544 | Sep 14, 2026 | Sep 16, 2021 – Dec 31, 2027 |
| Prime | Department of Health and Human Services National Institutes of Health | HHSN261201500003I; HHSN26100080; 400.001.0080.0001; NCI OD-FREDERICK; APPROPRIATED; 125073 BLDG. 560, ROOF EXHAUST STACKS; 9/24/2018 - 3/18/2022 | HHSN261201500003IUSAspending | $9,985,093 | Sep 11, 2026 | Sep 22, 2018 – Dec 31, 2026 |
| Prime | Department of Health and Human Services National Institutes of Health | IMPLEMENTATION AND CHARACTERIZATION OF IPSC-DERIVED CELL AND ORGANOID MODELS FOR INTEGRATION INTO NEW APPROACH METHODOLOGIES (NAMS) | 75N91019D00024USAspending | $1,323,885 | Sep 10, 2026 | Sep 21, 2026 – Sep 20, 2031 |
| Prime | Department of Health and Human Services National Institutes of Health | NIAID COVID-19 ACTIV3 | 75N91019D00024USAspending | $159,121,570 | Sep 9, 2026 | Sep 2, 2020 – Feb 28, 2027 |
| Prime | Department of Health and Human Services National Institutes of Health | HNGR(310)FC GMP3 CAMPAIGN AND OCTET METHOD DEVELOPMENT | 75N91019D00024USAspending | $9,231,560 | Sep 8, 2026 | Sep 16, 2019 – Sep 2, 2027 |
| Prime | Department of Health and Human Services National Institutes of Health | 126889 B571 REPLACE CHILLER #3 | 75N91019D00024USAspending | $1,291,828 | Sep 8, 2026 | Sep 8, 2026 – May 3, 2028 |
| Prime | Department of Health and Human Services National Institutes of Health | FY26 FFRDC LEASES | 75N91019D00024USAspending | $28,530,382 | Sep 4, 2026 | Aug 31, 2025 – Aug 30, 2026 |
| Prime | Department of Health and Human Services National Institutes of Health | FY26 125346 - B539 STORM DRAIN REPLACEMENT | 75N91019D00024USAspending | $1,064,983 | Sep 4, 2026 | Sep 8, 2026 – Jun 30, 2028 |
| Prime | Department of Health and Human Services National Institutes of Health | 126297 CAMPUS EVALUATE & REPLACE DEFICIENT ALTERNATING TREAD AND SHIP STAIRS | 75N91019D00024USAspending | $806,968 | Sep 3, 2026 | Sep 15, 2026 – Aug 23, 2028 |
| Prime | Department of Health and Human Services National Institutes of Health | CENTER FOR SEROLOGICAL SCIENCES NETWORK (SERONET) | 75N91019D00024USAspending | $79,896,408 | Sep 3, 2026 | Feb 10, 2021 – Oct 31, 2026 |
| Prime | Department of Health and Human Services National Institutes of Health | MD NET | 75N91019D00024USAspending | $181,379,395 | Sep 3, 2026 | Sep 26, 2019 – Oct 31, 2029 |
| Prime | Department of Health and Human Services National Institutes of Health | 126797 CAMPUS REPLACE BSCS | 75N91019D00024USAspending | $1,912,753 | Sep 3, 2026 | Sep 30, 2026 – Oct 25, 2028 |
| Prime | Department of Health and Human Services National Institutes of Health | NIAID VRC PRE-CLINICAL ASSESSMENT | 75N91019D00024USAspending | $16,097,583 | Aug 31, 2026 | Jun 17, 2024 – Aug 31, 2031 |
| Prime | Department of Health and Human Services National Institutes of Health | 126729 ROOM 524 D, E, F | 75N91019D00024USAspending | $1,102,374 | Aug 28, 2026 | Sep 8, 2026 – Oct 19, 2028 |
| Prime | Department of Health and Human Services National Institutes of Health | NIAID VRC FY26-27 OPERATIONAL TASK ORDER | 75N91019D00024USAspending | $87,806,507 | Aug 27, 2026 | Aug 31, 2025 – Aug 30, 2027 |
| Prime | Department of Health and Human Services National Institutes of Health | 126869 B539 & 560 - ROOF REPLACEMENTS | 75N91019D00024USAspending | $1,511,990 | Aug 27, 2026 | Sep 9, 2026 – May 5, 2028 |
| Prime | Department of Health and Human Services National Institutes of Health | FFRDC DRUG PRODUCT FORMULATION, MANUFACTURE, AND STABILITY STUDIES OF BETHANECHOL CHLORIDE FOR PHASE I CLINICAL TRIALS | 75N91019D00024USAspending | $1,644,574 | Aug 26, 2026 | Sep 21, 2026 – Sep 20, 2031 |
| Prime | Department of Health and Human Services National Institutes of Health | IGF::OT::IGF RESEARCH, DEVELOPMENT, PRODUCTION AND SUPPORT FOR CLINICAL TRIALS ? BROADLY NEUTRALIZING MONOCLONAL ANTIBODIES (BNMABS) | HHSN261201500003IUSAspending | $27,524,748 | Aug 25, 2026 | Sep 19, 2016 – Sep 18, 2021 |
| Prime | Department of Health and Human Services National Institutes of Health | CHARACTERIZATION OF MPOX | 75N91019D00024USAspending | $5,583,900 | Aug 24, 2026 | Sep 29, 2025 – Mar 28, 2027 |
| Prime | Department of Health and Human Services National Institutes of Health | FFRDC PTH-1A DRUG PRODUCT FOR PEDIATRIC DOSING | 75N91019D00024USAspending | $559,073 | Aug 24, 2026 | Sep 21, 2026 – Sep 20, 2030 |
| Prime | Department of Health and Human Services National Institutes of Health | 126864 MULTI BUILDING DRY CHEM FIRE SUPPRESSION SYSTEM | 75N91019D00024USAspending | $880,989 | Aug 24, 2026 | Sep 2, 2026 – Aug 21, 2028 |
| Prime | Department of Health and Human Services National Institutes of Health | COVID ACTIV3 TASK ORDER SUPPORTS NIAID'S GOAL TO BETTER UNDERSTAND THE CORONAVIRUS WITH AN INITIAL FOCUS ON ACTIV3. THIS TASK ORDER WILL INITIATE THE MANAGEMENT , OVERSIGHT , AND CONDUCT OF THE NIAID DCR CLINICAL TRIAL TITLED A MULTICENTER, ADA | 75N91019D00024USAspending | $9,492,218 | Aug 21, 2026 | Jun 30, 2020 – Jun 12, 2026 |
| Prime | Department of Health and Human Services National Institutes of Health | ELABORATION AND USE OF SYNGENIC PRE-CLINICAL MODELS FOR CANCER DRUG DEVELOPMENT | 75N91019D00024USAspending | $21,659,702 | Aug 21, 2026 | Sep 16, 2021 – Aug 21, 2029 |
| Prime | Department of Health and Human Services National Institutes of Health | FY25 FACILITIES TO E - 126663 B539 MISC SAFETY UPGRADES | 75N91019D00024USAspending | $1,676,963 | Aug 20, 2026 | Sep 4, 2025 – Jun 30, 2028 |
| Prime | Department of Health and Human Services National Institutes of Health | WEDGEWOOD EXPANSION DESIGN SUITES M & N | 75N91019D00024USAspending | $7,763,273 | Aug 19, 2026 | Sep 20, 2021 – Jan 26, 2027 |
| Prime | Department of Health and Human Services National Institutes of Health | FY25 FACILITIES TASK ORDER A - REPLACE WOOD STREET STEAM & CONDENSATE PIPING | 75N91019D00024USAspending | $3,035,294 | Aug 12, 2026 | May 7, 2025 – Sep 17, 2027 |
| Prime | Department of Health and Human Services National Institutes of Health | TAS::75 0849::TAS OPER OF GOVT R&D GOCO FACILITIES | — | $4,811,722,791 | Aug 7, 2026 | Sep 26, 2008 – Sep 6, 2024 |
| Prime | Department of Health and Human Services National Institutes of Health | DEVELOP, QUALIFY IMMUNOLOGICAL ASSAYS, AND PROVIDE CLINICAL SAMPLE TESTING FOR AAV-BASED GENE THERAPY CLINICAL CANDIDATES | 75N91019D00024USAspending | $4,557,516 | Aug 3, 2026 | Sep 15, 2025 – Sep 14, 2030 |
| Prime | Department of Health and Human Services National Institutes of Health | 126827 BUILDING 1023 ROOMS 8 AND 9 BSC REPLACEMENT | 75N91019D00024USAspending | $652,353 | Jul 30, 2026 | Jul 30, 2026 – Nov 15, 2027 |
| Prime | Department of Health and Human Services National Institutes of Health | FY25 FACILITIES TO G CONSTRUCTION OF BMP STRUCTURES FOR MDE STORM-WATER COMPLIANCE | 75N91019D00024USAspending | $2,670,576 | Jul 24, 2026 | Aug 21, 2025 – Sep 1, 2027 |
| Prime | Department of Health and Human Services National Institutes of Health | NIAID-VRC-MRNA VACCINE CAPABILITY ESTABLISHMENT | 75N91019D00024USAspending | $25,098,522 | Jul 22, 2026 | Sep 2, 2022 – Jun 17, 2030 |
| Prime | Department of Health and Human Services National Institutes of Health | THE OBJECTIVE OF THIS TASK ORDER SUPPORTS NIAIDS GOAL TO CONDUCT A SERIES OF STANDARDIZED PHASE 1 AND PHASE 2 TRIALS ON NEXT-GENERATION VACCINES TO GENERATE DATA TO INFORM DECISIONS ON WHICH CANDIDATES TO SUPPORT FOR ADVANCED DEVELOPMENT. | 75N91019D00024USAspending | $173,281,267 | Jul 22, 2026 | Jun 1, 2023 – May 31, 2029 |
| Prime | Department of Health and Human Services National Institutes of Health | MANUFACTURING CGMP GRADE HYDROXYCOBALAMINE | 75N91019D00024USAspending | $730,402 | Jul 20, 2026 | Sep 15, 2025 – Sep 14, 2030 |
Contract vehicles are shown only when present in the source record. Linked award numbers and vehicles open the authoritative record on USAspending.gov.
Agencies supported
- Department of Health and Human ServicesGov-sourced
Government-sourced data comes from SAM.gov, SBA and USAspending.gov and is attributed to its source. Items marked company-reported were provided by the company and are verified by FedSub only where labeled. FedSub is a private company and is not affiliated with SBA, GSA/SAM.gov, or any government agency.